Total Payments
$103,076
2024 Payments
$2,005
Companies
9
Transactions
68
Payment Breakdown by Category
Research$95,650 (92.8%)
Travel$4,345 (4.2%)
Food & Beverage$3,052 (3.0%)
Gifts$20.00 (0.0%)
Education$8.59 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $95,650 | 24 | 92.8% |
| Travel and Lodging | $4,345 | 21 | 4.2% |
| Food and Beverage | $3,052 | 21 | 3.0% |
| Gift | $20.00 | 1 | 0.0% |
| Education | $8.59 | 1 | 0.0% |
Payments by Type
Research
$95,650
24 transactions
General
$7,426
44 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Glenmark Pharmaceuticals Inc. | $72,450 | 7 | $0 (2017) |
| Circassia Pharmaceuticals Inc | $18,864 | 5 | $0 (2017) |
| PFIZER INC. | $6,835 | 22 | $0 (2024) |
| Allergan Inc. | $2,265 | 12 | $0 (2018) |
| ALK-Abello, Inc | $1,471 | 11 | $0 (2019) |
| Regeneron Pharmaceuticals, Inc. | $753.00 | 6 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $257.78 | 3 | $0 (2024) |
| BioCryst US Sales Co., LLC | $122.30 | 1 | $0 (2023) |
| Boston Scientific Corporation | $58.67 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,005 | 2 | PFIZER INC. ($1,900) |
| 2023 | $122.30 | 1 | BioCryst US Sales Co., LLC ($122.30) |
| 2022 | $119.85 | 1 | AstraZeneca Pharmaceuticals LP ($119.85) |
| 2021 | $20.00 | 1 | PFIZER INC. ($20.00) |
| 2019 | $3,594 | 19 | PFIZER INC. ($2,226) |
| 2018 | $2,493 | 17 | PFIZER INC. ($1,718) |
| 2017 | $94,721 | 27 | Glenmark Pharmaceuticals Inc. ($72,450) |
All Payment Transactions
68 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/30/2024 | PFIZER INC. | — | — | In-kind items and services | $1,900.00 | Research |
| Study: PF06760805 CLINICAL PUBLICATION PROGRAM | ||||||
| 07/22/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $105.28 | General |
| Category: Respiratory | ||||||
| 07/30/2023 | BioCryst US Sales Co., LLC | ORLADEYO (Drug) | Food and Beverage | In-kind items and services | $122.30 | General |
| Category: Immunology | ||||||
| 07/25/2022 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $119.85 | General |
| Category: Respiratory | ||||||
| 06/01/2021 | PFIZER INC. | — | Gift | In-kind items and services | $20.00 | General |
| 10/23/2019 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $73.10 | General |
| 09/23/2019 | ALK-Abello, Inc | Dust mite (D. farinae) (Biological) | Travel and Lodging | Cash or cash equivalent | $95.37 | General |
| 09/13/2019 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $389.11 | General |
| 09/13/2019 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $258.19 | General |
| 09/13/2019 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $223.47 | General |
| 08/24/2019 | ALK-Abello, Inc | Dust mite (D. farinae) (Biological) | Food and Beverage | In-kind items and services | $72.55 | General |
| 08/24/2019 | ALK-Abello, Inc | Dust mite (D. farinae) (Biological) | Food and Beverage | In-kind items and services | $40.93 | General |
| 08/24/2019 | ALK-Abello, Inc | Dust mite (D. farinae) (Biological) | Food and Beverage | In-kind items and services | $16.90 | General |
| 08/24/2019 | ALK-Abello, Inc | Dust mite (D. farinae) (Biological) | Food and Beverage | In-kind items and services | $16.90 | General |
| 08/23/2019 | ALK-Abello, Inc | Dust mite (D. farinae) (Biological) | Travel and Lodging | Cash or cash equivalent | $670.75 | General |
| 08/23/2019 | ALK-Abello, Inc | Dust mite (D. farinae) (Biological) | Travel and Lodging | Cash or cash equivalent | $192.20 | General |
| 08/23/2019 | ALK-Abello, Inc | Dust mite (D. farinae) (Biological) | Travel and Lodging | Cash or cash equivalent | $163.19 | General |
| 08/23/2019 | ALK-Abello, Inc | Dust mite (D. farinae) (Biological) | Food and Beverage | In-kind items and services | $91.26 | General |
| 08/23/2019 | ALK-Abello, Inc | Dust mite (D. farinae) (Biological) | Education | In-kind items and services | $8.59 | General |
| 02/18/2019 | PFIZER INC. | PREVNAR - 13 (Biological) | Travel and Lodging | In-kind items and services | $112.44 | General |
| Category: VACCINES | ||||||
| 01/18/2019 | PFIZER INC. | PREVNAR - 13 (Biological) | Food and Beverage | In-kind items and services | $427.93 | General |
| Category: VACCINES | ||||||
| 01/18/2019 | PFIZER INC. | PREVNAR - 13 (Biological) | Travel and Lodging | In-kind items and services | $370.24 | General |
| Category: VACCINES | ||||||
| 01/18/2019 | PFIZER INC. | PREVNAR - 13 (Biological) | Travel and Lodging | In-kind items and services | $270.07 | General |
| Category: VACCINES | ||||||
| 01/18/2019 | PFIZER INC. | PREVNAR - 13 (Biological) | Travel and Lodging | In-kind items and services | $101.27 | General |
| Category: VACCINES | ||||||
| 11/18/2018 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Food and Beverage | In-kind items and services | $32.65 | General |
| Category: Respiratory | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| GSP 301-303 | Glenmark Pharmaceuticals Inc. | $72,450 | 7 |
| A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis | Circassia Pharmaceuticals Inc | $18,864 | 5 |
| PF06760805 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,900 | 1 |
| A PHASE 23, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL AGN-241689 IN EPISODIC MIGRAINE PREVENTION. | Allergan Inc. | $876.00 | 2 |
| A Phase 23 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged 6 Months to 6 Years With Severe Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $753.00 | 6 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $451.00 | 2 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $356.00 | 1 |
About Dr. Nathan Segall, M.D
Dr. Nathan Segall, M.D is a Allergy & Immunology healthcare provider based in Stockbridge, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1619982444.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nathan Segall, M.D has received a total of $103,076 in payments from pharmaceutical and medical device companies, with $2,005 received in 2024. These payments were reported across 68 transactions from 9 companies. The most common payment nature is "" ($95,650).
Ad
Practice Information
- Specialty Allergy & Immunology
- Location Stockbridge, GA
- Active Since 07/30/2006
- Last Updated 09/18/2015
- Taxonomy Code 207RA0201X
- Entity Type Individual
- NPI Number 1619982444
Products in Payments
- Dust mite (D. farinae) (Biological) $1,369
- PREVNAR - 13 (Biological) $1,282
- DUPIXENT DUPILUMAB INJECTION (Biological) $753.00
- ORLADEYO (Drug) $122.30
- TEZSPIRE (Biological) $119.85
- FASENRA (Biological) $105.28
- Odactra (Drug) $102.17
- GENERAL BRONCHIAL THERMOPLASTY (Device) $58.67
- FASENRA (Drug) $32.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.